

June 23, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Change of Director

TOKYO, June 23, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo) today announced the change of director as follows:

Resignation of Director

Mr. Shigeo Kimura, Director and Senior Managing Corporate Officer, will resign on June 30, 2021 due to personal reasons.

The successor, Mr. Hiroaki Sekinaga, will be appointed as the Managing Corporate Officer and Head of Japan Business Unit, in accordance with a resolution of the Company's board of directors at a meeting of the board held on July 15, 2021. Mr. Sekinaga has a rich experience in the field of malignant lymphoma and, as the former Head of blood franchise at Chugai Pharmaceutical Co., Ltd., he has been consistently involved with rituximab, gazyva, and polatuzumab, which are concomitant drugs of our product, Treakisym®. As a member of SymBio at this time of its second inauguration, we expect that Mr. Sekinaga will spearhead the Company's growth.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125